Kronos Bio Inc
Change company Symbol lookup
Select an option...
KRON Kronos Bio Inc
GOVT iShares U.S. Treasury Bond ETF
BAC Bank of America Corp
$NQASPA50JPYN Nasdaq ASPA Industrials Net Total Re
SNP China Petroleum & Chemical Corp
GAEC Gulf Alternative Energy Corp
RDBX Redbox Entertainment Inc
AFG American Financial Group Inc
MRNA Moderna Inc
PFE Pfizer Inc
Go

Health Care : Biotechnology |
Company profile

Kronos Bio, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on the discovery and development of cancer therapeutics designed to target dysregulated transcription. Its product engine focuses on dysregulated transcription factors and the transcriptional regulatory networks (TRNs) that drive their oncogenic activity. Its lead product candidate, entospletinib (ENTO), is an orally administered, selective spleen tyrosine kinase (SYK) inhibitor that is being developed for the treatment of acute myeloid leukemia (AML). Its second product candidate, KB-0742, is generated from its product engine’s small molecule microarray (SMM) platform. KB-0742 is designed to be an orally bioavailable inhibitor of CDK9 with a differentiated selectivity profile. Its KB-0742 is in advanced solid tumors with MYC genomic copy number gain (amplification).

Closing Price
$12.29
Day's Change
-0.81 (-6.18%)
Bid
--
Ask
--
B/A Size
--
Day's High
13.74
Day's Low
12.29
Volume
(Average)
Volume:
213,815

10-day average volume:
220,047
213,815

Display:

Providers:

UpdateCancel
6 providers
November 24, 2021
Kronos Bio Announces Participation in Upcoming Investor Conferences

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in fireside chats at the following investor conferences: (Globe Newswire)

November 11, 2021
Kronos Bio Appoints Roshawn Blunt to Board of Directors

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Roshawn Blunt to the company's Board of Directors. Ms. Blunt has more than 25 years of experience in the...(Globe Newswire)

November 09, 2021
Kronos Bio Reports Recent Business Progress and Third-Quarter Financial Results

Company today announces progression of two discovery programs within its pipeline Highlights from the quarter include presentation of preclinical data on the company's CDK9 inhibitor KB-0742 at AACR-NCI-EORTC meeting in October; Kronos Bio remains...(Globe Newswire)

November 08, 2021
Kronos Bio and Tempus Announce Multi-Year Collaboration to Provide Kronos Bio With Access to Tempus' Platform

Kronos to receive broad access to Tempus' real-world data and proprietary tools and materials to expand preclinical hypotheses testing capabilities and inform more streamlined clinical trial design Agreement builds on earlier collaboration between...(Globe Newswire)

November 04, 2021
Kronos Bio Announces Participation in the BMO Biopharma Spotlight Series: Emerging Trends and Therapeutics in Oncology

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that Charles Lin, Ph.D., Senior Vice President, Biology, will participate in the Emerging Trends and Therapeutics in...(Globe Newswire)

September 30, 2021
Kronos Bio to Present Preclinical Data for KB-0742, an Oral CDK9 Inhibitor Targeting MYC-amplified Cancers, in Poster Presentation at AACR-NCI-EORTC 2021

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that it will present preclinical data in a poster at the AACR-NCI-EORTC Virtual International Conference on Molecular...(Globe Newswire)

September 14, 2021
Kronos Bio Appoints Marni Kottle as Senior Vice President of Corporate Communications and Investor Relations

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced the appointment of Marni Kottle as senior vice president of Corporate Communications and Investor Relations. Ms. Kottle...(Globe Newswire)

September 07, 2021
Kronos Bio Announces Participation in H.C. Wainwright 23rd Annual Global Investment Conference

Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that members of the management team will participate in a fireside chat at the H.C. Wainwright 23rd Annual Global Investment...(Globe Newswire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2021 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2021. All rights reserved.